A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

October 21, 2008

SMART Study: Viral Loads and Inflammation Explain Increased Cardio Risk

Untreated HIV may increase the risk of artery blockage and blood clots, according to new data from the international Strategies for the Management of Anti-Retroviral Therapy (SMART) published October 21 in the online journal PLoS Medicine. According to the SMART authors, a high viral load is associated with increases in specific proteins that have been linked to blood vessel inflammation and may explain higher rates of cardiovascular disease among HIV-positive people not on antiretroviral (ARV) treatment in the study.

Much has been written about the greater risk of heart attacks and deaths among people who interrupted or delayed ARV therapy in the SMART study. SMART compared people who remained on continuous ARV therapy with people who either delayed or stopped treatment until their CD4 counts fell below 250 cells. The study’s authors have suggested that uncontrolled HIV replication while people were off ARV therapy over-stimulated the body’s defense mechanisms, ultimately increasing the risk of cardiovascular disease. However, the exact mechanism by which this would have occurred has not been proved.

To determine the role of inflammatory markers in the risk of cardiovascular disease and deaths, Lewis Kuller, MD, PhD, from the University of Pittsburgh in Pennsylvania and his SMART colleagues examined stored blood samples from SMART study participants.

Kuller’s team first compared the levels of the six proteins between the 85 people who died of any cause in the study with the levels of 170 survivors of similar ages and other characteristics. The team found that three proteins—hsCRP, IL-6 and D-dimer—were significantly higher in those who died than in the survivors.

The team then looked for the relationship between these three inflammatory proteins and whether people remained on continuous treatment, with undetectable viral loads, or were off treatment, and thus had elevated viral loads. Higher levels of IL-6 and D-dimer, both of which have been tied to artery blockage (arteriosclerosis) and blood clots (thrombosis), were much more common in people with high viral loads.

The authors write that the association between deaths and the proteins IL-6 and D-dimer was particularly strong in the SMART study, even more so than in other studies that have examined the role of these inflammatory markers and cardiovascular disease and deaths in HIV-negative people. Moreover, because high IL-6 and D-dimer levels were more likely to be seen in people with higher viral loads, the authors state that viral replication most likely drives inflammation, which in turn is strongly associated with deaths. Kuller and his colleagues suggest that further research be conducted to confirm these results and to explore whether limiting inflammation could reduce the risk of death in people with HIV.

Search: Inflammation, SMART, INSIGHT, treatment interruption, Interleukin-6, IL6, C reactive protein, hsCRP, D-dimer, thrombosis, arteriosclerosis, heart attacks, deaths, cardiovascular, Lewis Kuller, University of Pittsburgh


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dulce_angelita
    Bronx
    New York


    Sin_Grinder
    Genoa
    Nevada


    MascGeek
    Houston
    Texas


    burke42
    Albany
    New York
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.